Conference Proceedings
The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative
Allison Barraclough, Edward Yoo, Chan Y Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M Johnston, Michael Dickinson, Stephen Opat, Zoe McQuilten, Erica M Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes
BLOOD | AMER SOC HEMATOLOGY | Published : 2019
Abstract
Background The time to treatment initiation is determined by tumour burden in patients with follicular lymphoma (FL). The Groupe d'Etude des Lymphomes Folliculaires ('GELF') criteria, defined in the pre-rituximab era, are commonly used to assess tumour burden.2 Patients must meet ≥1 of the following criteria to be considered "high" tumour burden according to GELF: any tumour mass >7 cm; ≥ 3 nodal sites (each >3 cm); B symptoms; splenomegaly; compression syndrome; pleural/peritoneal effusion; leukemic phase or cytopenias. Low tumour burden FL is often excluded from clinical trials, based on data from initial retrospective studies and later randomis..
View full abstract